ViiV Healthcare presents three-year switch data for Dovato (

The Phase III TANGO study is the third trial to provide long-term evidence for Dovato, reinforcing its use as a viable switch option for people living with HIV For media and investors only ViiV

Related Keywords

United States , Brentford , Hounslow , United Kingdom , North Carolina , Washington , London , City Of , Philadelphia , Pennsylvania , Middlesex , United Kingdom General , Kimberly Smith , Kathleen Quinn , Jeff Mclaughlin , Mick Readey , Audrey Abernathy , Tim Foley , James Dodwell , Kostenloser Wertpapierhandel , Olayemi Osiyemi , Melinda Stubbee , Glaxosmithkline , Nao Research Institute , Company Annual Report On Form , Pfizer Inc , O Medical Services , Viiv Healthcare , Head Of Research Development At Viiv Healthcare , Shionogi Limited , Tripleo Medical Services , Research Development , Per Protocol , Safety Information , Fetal Toxicity , Severe Hepatomegaly , Virologic Response Due , Drug Interactions , Reconstitution Syndrome , Prescribing Information , Antiretroviral Pregnancy Registry , Reproductive Potential , About Viiv , Annual Report , England Wales , West Road , Dose Combination , Based Regimen , Maintaining Virologic Suppression , Evaluate Dolutegravir Plus Lamivudine , Accessed September , Lviiv , Healthcare , Presents , Three , Ear , Switch , Data , Novato , Dolutegravir , Lamivudine , Aconfirming , Song , Term , Inferior , Efficacy , Irologic , Failure , Versus , Continuation , Ased , Regimens , Least , ,